Nicholas Butowski

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Timothy F. Cloughesy, Aaron Mochizuki, Joey Orpilla et al. · Nature Medicine · 2019 · 1.3K citations

Neuro-oncology, Neoadjuvant Anti-pd-1 Immunotherapy, Tumor Immunology +14

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Egfrviii-expressing Glioblastoma, Neuro-oncology, Act Iv +10

Association of Maximal Extent of Resection of Contrast-Enhanced and Non–Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma

Annette M. Molinaro, Shawn L. Hervey‐Jumper, Ramin A. Morshed et al. · JAMA Oncology · 2020 · 615 citations · Full text

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

Nicholas Butowski, Howard Colman, John de Groot et al. · Neuro-Oncology · 2015 · 562 citations · Full text

Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Burt Nabors, Jana Portnow, Manmeet S. Ahluwalia et al. · Journal of the National Comprehensive Cancer Network · 2020 · 538 citations · Full text

Surgical Oncology, Cancer Management, High-grade Gliomas +19